Silo Pharma旗下子公司Qwikagents正着手通过参与英伟达开发者计划，以加速其企业级人工智能智能体平台的研发进程。此举旨在利用英伟达先进的硬件与软件生态系统，赋能其AI解决方案，从而在竞争激烈的企业服务市场中占据更有利的技术高地。
通过接入该计划，Qwikagents将能够更深入地整合英伟达的计算平台与开发工具，这有望显著提升其AI智能体在处理复杂企业任务时的性能与效率。平台的发展重点预计将聚焦于自动化工作流、数据分析以及智能决策支持等核心企业应用场景。
这一战略合作动向，反映了AI技术与企业软件深度融合的行业趋势。对于Silo Pharma而言，支持Qwikagents的技术进阶，也是其探索在制药研发主线之外，于高增长科技领域进行战略布局的一部分。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.